Aim-To investigate overexpression of cerbB2, expression ofthe p53 protein product and proliferation rates in benign breast lesions with specific reference to apocrine adenosis. Methods-Twenty one cases of apocrine adenosis were stained with monoclonal antibodies to p185, the protein product of the c-erbB2 oncogene, the protein product of the p53 tumour suppressor gene and to the cell cycle related protein Ki67. Three cases were associated with concomitant ductal carcinoma in situ of large cell type and two were associated with invasive tubular or cribriform carcinoma. Results-Twelve (57.1%) cases showed membrane staining for c-erbB2 oncoprotein of apocrine cells within sclerosing adenosis and six (28.6%) had occasional p53 protein positive cells. One case not associated with carcinoma showed extensive staining of apocrine metaplasia outside the area of apocrine adenosis. The proliferation rate, as measured by Ki67 staining, was increased in some of the lesions and all lesions showed at least some of the cells to be in the cell cycle. Conclusions-The expression ofabnormal oncogene products and increased proliferation in some ofthese apocrine lesions questions the supposed degenerative nature of the atypia seen in such cases and suggests that there may be an association between these lesions and large cell ductal carcinoma in situ and hence invasive carcinoma. (J Clin Pathol 1995;48:737-742) 
Several studies have emphasised the increased risk of subsequent breast carcinoma associated with fibrocystic change of about x 2 5 seen epidemiologically.' Some studies have indeed identified lesions which carry an increased incidence of subsequent malignancy such as atypical ductal hyperplasia," atypical lobular hyperplasia4 and multiple papillomas. 5 Most of these lesions develop into small cell micropapillary or cribriform carcinoma in situ and thereafter into invasive ductal or lobular carcinoma. Precursor lesions for large cell comedo or solid type ductal carcinoma in situ have not been identified as yet.
C-erbB2 is an oncogene present on chromosome 1 7q which codes for a 185 kDa protein (p185) with tyrosine kinase receptor function analogous to the epidermal growth factor receptor. The p185 receptor is overexpressed in about 20% of invasive breast carcinomas6 7 but is more frequently overexpressed in large cell comedo carcinoma in situ' in about 80% of cases. It has been postulated that overexpression of this oncoprotein is an early event in the genesis of some types ofbreast carcinoma and that subsequently the receptor may be lost once a tumour has become invasive.
p53 is a tumour suppressor gene which is present on chromosome 17p. This gene codes for a protein which is mutated in certain families as a genetic event associated with childhood sarcomas and ovarian carcinoma.9 It is also found as a sporadic event in some breast carcinomas known not to be familial. The wildtype protein has a short half life and is not normally detected by immunocytochemistry except in extreme cases of DNA damage, but mutant forms of the protein may accumulate and become detectable.'0 Ki67 is an antibody that recognises a cell cycle related nuclear antigen, which is thought to be expressed in the G1, S, G2, and M phases of the cell cycle but not in GO." Percentage scores for carcinomas have been shown to vary with the type of tumour from 2 25% in tubular carcinoma to 63-95% in others. '2 We have studied 21 cases of apocrine adenosis, three associated with ductal carcinoma in situ and two with invasive carcinoma, by immunocytochemistry using antibodies to the c-erbB2 oncoprotein, p53 protein and the proliferation related antigen Ki67. Control cases of normal breast tissue, apocrine metaplasia and sclerosing adenosis were also studied to determine the level of proliferation, c-erbB2 oncoprotein expression and p53 positivity in these conditions in the absence of apocrine adenosis.
Methods
Cases of apocrine adenosis (figs 1 and 2) were collected from the files of the histopathology departments of St Bartholomew's Hospital, London, and Southmead Hospital Breast Pathology Unit. Some of these cases had been sent to CAW and JDD as referrals. The details of the cases are given in table 1 throughout the tissue (fig 4) 6) . Four of the five cases associated with carcinoma were stained with the Ki67 antibody and these showed a mean percentage positivity of 8-06% (range 2-7 to 14-8%). The results are summarised in table 2. The 36 control cases of normal breast epithelium stained had a mean positivity of 0 93% (range 0 to 7%). Twenty eight cases of unselected apocrine metaplasia showed a mean percentage positivity of 1d1% (range 0 to 9%).
Twenty five cases of unselected sclerosing adenosis had a mean positivity of 4-8% (range 0 to 17%). This was primarily due to two cases, Although there may be a progression from small cell to large cell carcinoma in situ in some cases, this is not generally seen and the prereactivity of cursor lesion of the commoner large cell ductal carcinoma in situ of solid, comedo or large cell micropapillary type has thus far not been Ki67(0%) identified.
Haagensen'0 found a fivefold increased in- 4 cidence of carcinoma associated with papillary 1-5 apocrine metaplasia in fibrocystic change al- 8.3 though this has subsequently been ques- enosis." However, the follow up period for these lesions in the literature is rather short. high intensity
The positive staining for c-erbB2 in apocrine + = low sn adenosis suggests that at least some of these lesions are overexpressing this oncogene and hence may not be degenerative as has been suggested. ' seen in carcinomas.9 Antibody detection of accumulated protein is generally thought to be related to the formation of a mutant protein which is not destroyed effectively. Very sensitive enhanced immunocytochemical techniques could theoretically detect small amounts of the wild-type protein especially in lesions with DNA damage; however, the method used here is the standard technique without enhancement and no positive cases were detected among the unselected cases of apocrine metaplasia, normal epithelium or sclerosing adenosis. The finding, therefore, of some cases showing accumulation ofimmunoreactive protein suggests that some of these cases may have a mutation in the p53 gene. The antibody used cannot detect cases where both alleles of the p53 gene are absent and hence the protein is not being produced, and the antibody may also not detect occasional cases where mutation is in the region recognised by the antibody.
Abnormal oncogene expression by apocrine cells has been suggested before27 using antibodies to ras and c-myc. Increased proliferation, however, has not been shown to be a feature of apocrine metaplasia2" and some authors believe that apocrine metaplasia in general is a terminally differentiated lesion,2829 a suggestion generally supported by the low proliferation rate in the unselected series of apocrine metaplasia tested here. Apocrine adenosis, however, has not been specifically studied using these methods. The results of the Ki67 staining in these lesions is variable but four cases not associated with carcinoma showed a marked increase in proliferation rate comparable with that found in some carcinomas.'2 This suggests that in some of these specific lesions the apocrine cells are not necessarily terminally differentiated and are still undergoing proliferation. In the series of unselected apocrine metaplastic lesions two cases showed proliferation rates of 8 and 9%, respectively. One of these was a case with cytoplasmic positivity for c-erbB2 and atypical ductal hyperplasia elsewhere in the tissue. The other was an unusual case of florid papillary apocrine metaplasia. Three cases of myoepithelial cell proliferation in the florid phase of sclerosing adenosis also showed high proliferation rates but epithelial proliferation was not a feature.
If the time course from the precursor lesion to the development of large cell ductal carcinoma in situ is short and the disease starts in a unifocal fashion spreading down the duct system and becoming invasive in multiple areas, as is seen in some large cell ductal carcinomas in situ detected by breast cancer screening, then the precursor lesion is likely to be a rare phenomenon. If this putative precursor lesion was unifocal and completely or partially excised and subsequently destroyed by the tissue reaction to surgery, it may well be eradicated and the premalignant nature of the lesion may go unrecognised in long term follow up studies.
If apocrine adenosis was to be associated with large cell ductal carcinoma in situ, then it may be possible to find areas of apocrine adenosis associated with ductal carcinoma. If 
